HHS Secretary Announces Intent to Extend HHS-OIG Exclusion Authority to CMS, Expanding the Administration’s Anti-Fraud Campaign
HHS Secretary Robert F. Kennedy Jr. recently announced that he would give CMS the authority to exclude individuals and entities from participation in federal health care programs, an authority previously held only by HHS-OIG. While the announcement has not been formalized since announced in July, the announcement signals a potentially far-reaching expansion of CMS’s enforcement powers, which in turn would have implications for healthcare providers, suppliers, manufacturers, vendors, and other industry stakeholders.
When AI Changes The Deal: Seven AI-related Considerations for Life Sciences M&A Dealmakers
Sally Wagner Partin, Sharon R. Flanagan, and Torrey Cope consider how AI is reshaping drug development, particularly at the stages of target and compound identification, and set out the implications of those changes for valuation, diligence, risk, milestone design, and timing in life sciences transactions.
